Assessing human health response in life cycle assessment using ED10s and DALYs:: Part 2 -: Noncancer effects

被引:56
作者
Pennington, D
Crettaz, P
Tauxe, A
Rhomberg, L
Brand, K
Jolliet, O [1 ]
机构
[1] Swiss Fed Inst Technol, Life Cycle Syst, CH-1015 Lausanne, Switzerland
[2] Ecole Polytech Fed Lausanne, GECOS, DGR, ENAC, CH-1015 Lausanne, Switzerland
[3] Gradient Corp, Cambridge, MA 02142 USA
[4] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada
关键词
life cycle impact assessment (LCA); toxicity characterization factors; noncancer; dose-response curve; human health; DALY;
D O I
10.1111/1539-6924.00263
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In Part 1 of this article we developed an approach for the calculation of cancer effect measures for life cycle assessment (LCA). In this article, we propose and evaluate the method for the screening of noncancer toxicological health effects. This approach draws on the noncancer health risk assessment concept of benchmark dose, while noting important differences with regulatory applications in the objectives of an LCA study. We adopt the central tendency estimate of the toxicological effect dose inducing a 10% response over background, ED10, to provide a consistent point of departure for default linear low-dose response estimates (beta(ED10)). This explicit estimation of low-dose risks, while necessary in LCA, is in marked contrast to many traditional procedures for noncancer assessments. For pragmatic reasons, mechanistic thresholds and nonlinear low-dose response curves were not implemented in the presented framework. In essence, for the comparative needs of LCA, we propose that one initially screens alternative activities or products on the degree to which the associated chemical emissions erode their margins of exposure, which may or may not be manifested as increases in disease incidence. We illustrate the method here by deriving the betaED(10) slope factors from bioassay data for 12 chemicals and outline some of the possibilities for extrapolation from other more readily available measures, such as the no observable adverse effect levels (NOAEL), avoiding uncertainty factors that lead to inconsistent degrees of conservatism from chemical to chemical. These extrapolations facilitated the initial calculation of slope factors for an additional 403 compounds; ranging from 10(-6) to 10(3) (risk per mg/kg-day dose). The potential consequences of the effects are taken into account in a preliminary approach by combining the beta(ED10) with the severity measure disability adjusted life years (DALY), providing a screening-level estimate of the potential consequences associated with exposures, integrated over time and space, to a given mass of chemical released into the environment for use in LCA.
引用
收藏
页码:947 / 963
页数:17
相关论文
共 69 条
[1]   DOSE-RESPONSE ASSESSMENT FOR DEVELOPMENTAL TOXICITY .3. STATISTICAL-MODELS [J].
ALLEN, BC ;
KAVLOCK, RJ ;
KIMMEL, CA ;
FAUSTMAN, EM .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1994, 23 (04) :496-509
[2]   DOSE-RESPONSE ASSESSMENT FOR DEVELOPMENTAL TOXICITY .2. COMPARISON OF GENERIC BENCHMARK DOSE ESTIMATES WITH NO OBSERVED ADVERSE EFFECT LEVELS [J].
ALLEN, BC ;
KAVLOCK, RJ ;
KIMMEL, CA ;
FAUSTMAN, EM .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1994, 23 (04) :487-495
[3]  
[Anonymous], 1999, Priority assessment of toxic substances in LCA. Development and application of the multi-media fate
[4]  
[Anonymous], CRITICAL SURFACE TIM
[5]  
[Anonymous], LCA NEWS
[6]  
[Anonymous], 1996, METHODOLOGY LIFE CYC
[7]  
[Anonymous], 1995, 68 ECETOC
[8]   Noncancer risk assessment: A probabilistic alternative to current practice [J].
Baird, SJS ;
Cohen, JT ;
Graham, JD ;
Shlyakhter, AI ;
Evans, JS .
HUMAN AND ECOLOGICAL RISK ASSESSMENT, 1996, 2 (01) :79-102
[9]   Life Cycle Impact Assessment Workshop Summary Midpoints versus Endpoints: The Sacrifices and Benefits [J].
Bare, Jane C. ;
Hofstetter, Patrick ;
Pennington, David W. ;
de Haes, Helias A. Udo .
INTERNATIONAL JOURNAL OF LIFE CYCLE ASSESSMENT, 2000, 5 (06) :319-326
[10]   BENCHMARK DOSE WORKSHOP - CRITERIA FOR USE OF A BENCHMARK DOSE TO ESTIMATE A REFERENCE DOSE [J].
BARNES, DG ;
DASTON, GP ;
EVANS, JS ;
JARABEK, AM ;
KAVLOCK, RJ ;
KIMMEL, CA ;
PARK, C ;
SPITZER, HL .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1995, 21 (02) :296-306